MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Vertex Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

484.45 0.24

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

481.39

Max

493

Schlüsselkennzahlen

By Trading Economics

Einkommen

-132M

913M

Verkäufe

142M

2.9B

KGV

Branchendurchschnitt

30.42

63.778

EPS

3.98

Gewinnspanne

31.353

Angestellte

6,100

EBITDA

-99M

1.2B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+3.23% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.8B

127B

Vorheriger Eröffnungskurs

484.21

Vorheriger Schlusskurs

484.45

Nachrichtenstimmung

By Acuity

13%

87%

16 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Feb. 2025, 22:11 UTC

Ergebnisse

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31. Jan. 2025, 00:19 UTC

Wichtige Markttreiber

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19. Dez. 2024, 12:25 UTC

Wichtige Markttreiber

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4. Nov. 2024, 21:44 UTC

Ergebnisse

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1. Aug. 2024, 20:45 UTC

Ergebnisse

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. Feb. 2025, 21:12 UTC

Ergebnisse

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11. Feb. 2025, 14:21 UTC

Ergebnisse

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10. Feb. 2025, 21:12 UTC

Ergebnisse

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10. Feb. 2025, 21:12 UTC

Ergebnisse

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10. Feb. 2025, 21:11 UTC

Ergebnisse

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10. Feb. 2025, 21:04 UTC

Ergebnisse

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10. Feb. 2025, 21:04 UTC

Ergebnisse

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10. Feb. 2025, 21:02 UTC

Ergebnisse

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10. Feb. 2025, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10. Feb. 2025, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10. Feb. 2025, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10. Feb. 2025, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31. Jan. 2025, 09:59 UTC

Heiße Aktien

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4. Nov. 2024, 22:21 UTC

Ergebnisse

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4. Nov. 2024, 21:25 UTC

Ergebnisse

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4. Nov. 2024, 21:03 UTC

Ergebnisse

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4. Nov. 2024, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4. Nov. 2024, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4. Nov. 2024, 21:01 UTC

Ergebnisse

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26. Sept. 2024, 14:20 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1. Aug. 2024, 20:30 UTC

Ergebnisse

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1. Aug. 2024, 20:03 UTC

Ergebnisse

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1. Aug. 2024, 20:02 UTC

Ergebnisse

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1. Aug. 2024, 20:02 UTC

Ergebnisse

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Peer-Vergleich

Kursveränderung

Vertex Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

3.23% Vorteil

12-Monats-Prognose

Durchschnitt 499.09 USD  3.23%

Hoch 591 USD

Tief 320 USD

Basierend auf 27 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vertex Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

27 ratings

16

Buy

10

Halten

1

Sell

Technischer Score

By Trading Central

480.95 / 505.49Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

16 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.